ELUTElutia Inc. Class A Common Stock

CEO Mills reports 96% surgeon interest in NXT-41x platform ahead of late 2026 FDA clearance.

Moby summary of Elutia Inc.'s Q2 2026 earnings call

Elutia Inc (ELUT) reports Q2 2026 results, highlighting robust surgeon interest in NXT41X and a strengthened balance sheet despite a slight revenue dip.

Bernadine Cherniak: Thank you, operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the first quarter ended March 31, 2026. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Moby summary of Elutia Inc.'s Q1 2026 earnings call

Elutia Inc (ELUT) reports a 6% increase in total net sales and significant progress in its NXT-41 regulatory program, despite challenges in SimpliDerm revenue and increased net loss.

Elutia Inc (ELUT) reports a 16% revenue increase and improved gross margins, while navigating operational losses and strategic product shifts.

Moby summary of Elutia Inc.'s Q4 2025 earnings call

Earlier today, Elutia Inc. released financial results for the fourth quarter and full year ended 12/31/2025. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements contained in this call that do not relate to matters of historical fact or relate to expectations, predictions of future events, results, or performance are forward-looking statements.

Whilst it may not be a huge deal, we thought it was good to see that the Elutia Inc. ( NASDAQ:ELUT ) Independent...